CVS, UnitedHealth ask for FTC's Khan and 2 commissioners to be disqualified from case
By Amina Niasse
NEW YORK, Oct 9 (Reuters) -CVS Health CVS.N and UnitedHealth Group UNH.N have asked U.S. Federal Trade Commission chair Lina Khan and commissioners Rebecca Kelly Slaughter and Alvaro Bedoya to disqualify themselves from an FTC lawsuit that has accused the companies of unlawfully inflating insulin prices.
The companies provided the motions to Reuters after filing them late on Tuesday with the FTC's in-house court. They said that Khan, along with Slaughter and Bedoya, displayed bias against pharmacy benefit managers and prejudged their pricing models.
CVS pointed to the commissioners' claims that volume-based discounts, or rebates, lead to higher prices for patients, and to Khan's appearance at a National Community Pharmacist Association event in 2022. The group, made up of independent pharmacists, has criticized pharmacy benefit managers.
"Event participants wore anti-PBM paraphernalia, including pins that vilified PBMs as “bloodsuckers” and shirts depicting PBMs as vampires," the document read.
UnitedHealth said that the commissioners' appearances at anti-pharmacy benefit manager events showed their prejudice.
The FTC suit accuses CVS Health's Caremark, UnitedHealth's Optum, and Cigna's CI.N Express Scripts of unfairly limiting access to insulin drugs with lower list prices and steering patients toward more expensive drugs to increase the spread of profit generated from negotiated discounts.
Express Scripts also supported the CVS complaint.
CVS's response also pointed to statements published by the commissioners in 2022, stating PBMs exclude cheaper generics from plans and 2024 congressional testimony describing PBMs as "middlemen" between drugmakers and patients seeking access to medications.
In recent years, both Amazon AMZN.O and Meta's META.O Facebook tried and failed to have Khan removed from their antitrust cases.
Reporting by Amina Niasse; Editing by Caroline Humer and Muralikumar Anantharaman
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
